Join
Live feed
·
PRReleasevia Quantisnow
Amgen Inc. logo

AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL

ByQuantisnow·Wall Street's wire, on your screen.
AMGN· Amgen Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AMGN (Amgen Inc.) and more on Quantisnow.